{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407802464
| IUPAC_name = (3''S'')-2-[(2''S'')-2-<nowiki>[[</nowiki>(2''S'')-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1''H''-isoquinoline-3-carboxylic acid
| image = Moexipril.svg
| width = 250

<!--Clinical data-->
| tradename = Univasc
| Drugs.com = {{drugs.com|monograph|moexipril-hydrochloride}}
| MedlinePlus = a695018
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = D
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 13-22%
| protein_bound = 90%
| metabolism = [[Hepatic]] (active metabolite, moexiprilat)
| elimination_half-life = 1 hour; 2-9 hours (active metabolite)
| excretion =  50% (faeces), 13% (urine)
<!--Identifiers-->
| IUPHAR_ligand = 6571
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 103775-10-6
| ATC_prefix = C09
| ATC_suffix = AA13
| ATC_supplemental =  
| PubChem = 91270
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00691
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 82418
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = WT87C52TJZ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08225
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1165
<!--Chemical data-->
| C=27 | H=34 | N=2 | O=7
| molecular_weight = 498.568 g/mol
}}

'''Moexipril''' hydrochloride is a potent orally active nonsulfhydryl [[angiotensin converting enzyme inhibitor]] (ACE inhibitor)<ref>{{cite book|title=The AARP Guide to Pills|editor=Hochadel, Maryanne|publisher=Sterling Publishing Company|year=2006|page=640|isbn=978-1-4027-1740-6|url=https://books.google.com/books?id=WvcaI-7TuaMC&pg=RA1-PA64|accessdate=2009-10-09}}</ref> which is used for the treatment of [[hypertension]] and [[congestive heart failure]]. Moexipril can be administered alone or with other [[antihypertensives]] or [[diuretics]].<ref name="development">Belal, F.F, K.M. Metwaly, and S.M. Amer. "Development of Membrane Electrodes for the Specific Determination of Moexipril Hydrochloride in Dosage Forms and Biological Fluids." Portugaliae Electrochimica Acta. 27.4 (2009): 463-475.</ref> It works by inhibiting the conversion of [[angiotensin I]] to [[angiotensin II]].<ref name="newdrug">Rodgers, Katie, Michael C Vinson, and Marvin W Davis. "Breakthroughs: New drug approvals of 1995 -- part 1." Advanstar Communications, Inc. 140.3 (1996): 84.</ref> Moexipril is available from Schwarz Pharma under the trade name '''Univasc'''.<ref name="newdrug" /><ref>{{cite book|last=Dart|first=Richard C.|title=Medical toxicology|publisher=Lippincott Williams & Wilkins|year=2004|page=647|isbn=978-0-7817-2845-4|url=https://books.google.com/books?id=BfdighlyGiwC&pg=PA647|accessdate=2009-10-09}}</ref>

==Pharmacology==
[[File:Moexiprilat.svg|thumb|left|Moexiprilat — the active metabolite of moexipril]]
Moexipril is available as a [[prodrug]] moexipril hydrochloride, and is metabolized in the liver to form the pharmacologically active compound moexiprilat. Formation of moexiprilat is caused by hydrolysis of an [[ethyl ester]] group.<ref>{{Cite journal|pages= 101–106|pmid=17266629|year=2007|author1=Kalász|first1=H|title=Metabolism of moexipril to moexiprilat: Determination of in vitro metabolism using HPLC-ES-MS|journal=Medicinal chemistry (Shariqah (United Arab Emirates))|volume=3|issue=1|last2=Petroianu|first2=G|last3=Tekes|first3=K|last4=Klebovich|first4=I|last5=Ludányi|first5=K|last6=Gulyás|first6=Z|doi=10.2174/157340607779317490}}</ref> Moexipril is incompletely absorbed after oral administration, and its [[bioavailability]] is low.<ref>Chrysant, George S, PK Nguyen. “Moexipril and left ventricular hypertrophy.” Vascular Health Risk Management. 3.1 (2007): 23-30.</ref> The long pharmacokinetic [[half-life]] and persistent ACE inhibition of moexipril allows once-daily administration.<ref name="duration">{{Cite journal|pmid=11837383|pages= 9–17|year= 2002|author1= Cawello|first1= W|title= Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition|journal= International journal of clinical pharmacology and therapeutics|volume= 40|issue= 1|last2= Boekens|first2= H|last3= Waitzinger|first3= J|last4= Miller|first4= U|doi=10.5414/cpp40009}}</ref>

Moexipril is highly [[lipophilic]],<ref name="development" /> and is in the same hydrophobic range as [[quinapril]], [[benazepril]], and [[ramipril]].<ref name="duration" /> Lipophilic ACE inhibitors are able to penetrate membranes more readily, thus tissue ACE may be a target in addition to plasma ACE. A significant reduction in tissue ACE (lung, myocardium, aorta, and kidney) activity has been shown after moexipril use.<ref name="remodel">{{Cite journal|pmid=9488609|pages= 21–30|year= 1998|author1= Chrysant|first1= S. G.|title= Vascular remodeling: The role of angiotensin-converting enzyme inhibitors|journal= American Heart Journal|volume= 135|issue= 2 Pt 2}}</ref>

It has additional [[Phosphodiesterase-4 inhibitor|PDE4-inhibiting]] effects.<ref>{{cite journal|title=Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)|journal=Biochemical Pharmacology|date=May 2013|volume=85|issue=9|pages=1297–1305|author1=Cameron, RT |author2=Coleman, RG |author3=Day, JP |author4=Yalla, KC |author5=Houslay, MD |author6=Adams, DR |author7=Shoichet, BK |author8=Baillie, GS |doi=10.1016/j.bcp.2013.02.026|pmid=23473803|pmc=3625111}}</ref>

{{clear left}}

==Side effects==
Moexipril is generally well tolerated in elderly patients with hypertension.<ref name="safety">{{cite journal|pmid=8583466|pages=879–884|year=1995|author1=White|first1=W. B.|title=Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension|journal=Journal of Human Hypertension|volume=9|issue=11|last2=Stimpel|first2=M}}</ref>
Hypotension, dizziness, increased cough, diarrhea, flu syndrome, fatigue, and flushing have been found to affect less than 6% of patients who were prescribed moexipril.<ref name="newdrug" /><ref name="safety" />

==Mechanism of action==
As an ACE inhibitor, moexipril causes a decrease in ACE. This blocks the conversion of angiotensin I to angiotensin II. Blockage of angiotensin II limits hypertension within the vasculature. Additionally, moexipril has been found to possess cardioprotective properties. Rats given moexipril one week prior to induction of [[myocardial infarction]], displayed decreased infarct size.<ref>{{Cite journal|pmid=8837552|pages=803–812|year=1996|author1=Rosendorff|first1=C|title=The renin-angiotensin system and vascular hypertrophy|journal=Journal of the American College of Cardiology|volume=28|issue=4|doi=10.1016/s0735-1097(96)00251-3}}</ref> The cardioprotective effects of ACE inhibitors are mediated through a combination of angiotensin II inhibition and [[bradykinin]] proliferation.<ref name="remodel" /><ref name="hartman">Hartman, J.C. “The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.” The Annals of Thoracic Surgery. 60.3 (1995): 789-792.</ref> Increased levels of bradykinin stimulate in the production of [[prostaglandin E2|prostaglandin E<sub>2</sub>]]<ref>{{cite journal | author = Jaiswal N, Diz DI, Chappell MC, Khosia MC, Ferrario CM | year = 1992 | title = Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors | doi = 10.1161/01.hyp.19.2_suppl.ii49 | journal = Hypertension | volume = 19 | issue = 2| pages = 49–55 }}</ref> and nitric oxide,<ref name="hartman" /> which cause vasodilation and continue to exert antiproliferative effects.<ref name="remodel" /> Inhibition of angiotensin II by moexipril decreases remodeling effects on the cardiovascular system. Indirectly, angiotensin II stimulates of the production of [[endothelin]] 1 and 3 (ET1, ET3)<ref>Phillips, PA. “Interaction between endothelin and angiotensin II.” Clinical and Experimental Pharmacology and Physiology. 26.7. (1999): 517-518.</ref> and the transforming growth factor beta-1 ([[TGF-β1]]),<ref>{{cite journal|pmid=10505424|pages=246–253|year=1999|author1=Youn|first1=T. J.|title=Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: Effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade|journal=Basic research in cardiology|volume=94|issue=4|last2=Kim|first2=H. S.|last3=Oh|first3=B. H.|doi=10.1007/s003950050149}}</ref> all of which have tissue proliferative effects that are blocked by the actions of moexipril.  The antiproliferative effects of moexipril have also been demonstrated by ''[[in vitro]]'' studies where moexipril inhibits the estrogen-stimulated growth of neonatal cardiac [[fibroblasts]] in rats.<ref name="hartman" /> Other ACE inhibitors have also been found to produce these actions, as well.

== Synthesis ==
[[File:Moexipril synthesis.svg|thumb|center|500px|Moexipril synthesis:<ref>M. L. Hoefle, S. Klutchko, {{cite patent|EP|49605}}; eidem, {{US patent|4344949}} (both 1982 to [[Warner-Lambert]]).</ref><ref>{{cite journal|doi=10.1021/jm00160a026|pmid=3020249|title=Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types|journal=Journal of Medicinal Chemistry|volume=29|issue=10|pages=1953–61|year=1986|last1=Klutchko|first1=Sylvester|last2=Blankley|first2=C. John|last3=Fleming|first3=Robert W.|last4=Hinkley|first4=Jack M.|last5=Werner|first5=Ann E.|last6=Nordin|first6=Ivan|last7=Holmes|first7=Ann|last8=Hoefle|first8=Milton L.|last9=Cohen|first9=David M.|last10=Essenburg|first10=A. D.}}</ref>]]
The synthesis of the all-important dipeptide-like side chain involves alkylation of the ''tert''-butyl ester of <small>L</small>-alanine ('''2''') with ethyl 2-bromo-4-phenylbutanoate ('''1'''); the presominane of the desired isomer is attributable to [[asymmetric induction]] from the adjacent chiral center. Reaction of the product with hydrogen chloride then cleaves the ''tert''-butyl group to give the half acid ('''3''').<ref>{{cite journal|doi=10.1080/00304948309355428|title=SYNTHESIS OF [S-(R∗,R∗)] – ETHYL α–[(1–CARBOXYETHYL) AMINO]–BENEZENEBUTANOATE, AN IMPORTANT INTERMEDIATE IN THE SYNTHESIS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS|journal=Organic Preparations and Procedures International|volume=15|pages=35|year=2009|last1=Kaltenbronn|first1=James S.|last2=Dejohn|first2=Dana|last3=Krolls|first3=Uldis}}</ref> Coupling of that acid to the secondary amine on [[tetrahydroisoquinoline]] ('''4''') gives the corresponding amine. The ''tert''-butyl ester in this product is again cleaved with [[hydrogen chloride]] to afford moexipril ('''5''').

==References==
{{Reflist}}

{{ACE inhibitors}}
{{Angiotensin receptor modulators}}

[[Category:ACE inhibitors]]
[[Category:Butyrates]]
[[Category:Enantiopure drugs]]
[[Category:Ethyl esters]]
[[Category:Phenol ethers]]
[[Category:Prodrugs]]
[[Category:Tetrahydroisoquinolines]]